These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Mewshaw RE; Nelson JA; Shah US; Shi X; Mazandarani H; Coupet J; Marquis K; Brennan JA; Andree TH Bioorg Med Chem Lett; 1999 Sep; 9(17):2593-8. PubMed ID: 10498215 [TBL] [Abstract][Full Text] [Related]
65. pH dependency of ligand binding to cellobiohydrolase 1 (Cel7A). Affinity, selectivity and inhibition for designed propranolol analogues. Fagerström A; Nilsson M; Berg U; Isaksson R J Chromatogr A; 2007 Jan; 1138(1-2):276-83. PubMed ID: 17141791 [TBL] [Abstract][Full Text] [Related]
66. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo]. Abaimov DA; Zimin IA; Kovalev GI Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481 [TBL] [Abstract][Full Text] [Related]
67. In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. Stark D; Piel M; Hübner H; Gmeiner P; Gründer G; Rösch F Bioorg Med Chem; 2007 Nov; 15(21):6819-29. PubMed ID: 17765546 [TBL] [Abstract][Full Text] [Related]
68. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes. Odagaki Y; Toyoshima R Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659 [TBL] [Abstract][Full Text] [Related]
69. Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors. Vendrell M; Soriano A; Casadó V; Díaz JL; Lavilla R; Canela EI; Lluís C; Franco R; Albericio F; Royo M ChemMedChem; 2009 Sep; 4(9):1514-22. PubMed ID: 19557804 [TBL] [Abstract][Full Text] [Related]
70. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032 [TBL] [Abstract][Full Text] [Related]
71. The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors. Seeman P; Tokita K; Matsumoto M; Matsuo A; Sasamata M; Miyata K Synapse; 2009 Oct; 63(10):930-4. PubMed ID: 19588469 [TBL] [Abstract][Full Text] [Related]
72. Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Awadallah FM; Müller F; Lehmann J; Abadi AH Bioorg Med Chem; 2007 Sep; 15(17):5811-8. PubMed ID: 17576067 [TBL] [Abstract][Full Text] [Related]
73. Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features. Malo M; Brive L; Luthman K; Svensson P ChemMedChem; 2010 Feb; 5(2):232-46. PubMed ID: 20077461 [TBL] [Abstract][Full Text] [Related]
74. Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Sipos A; Csutorás C; Berényi S; Uustare A; Rinken A Bioorg Med Chem; 2008 Apr; 16(8):4563-8. PubMed ID: 18313931 [TBL] [Abstract][Full Text] [Related]
75. Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. Claudi F; Giorgioni G; Di Stefano A; Abbracchio MP; Paoletti AM; Balduini W J Med Chem; 1992 Nov; 35(23):4408-14. PubMed ID: 1360027 [TBL] [Abstract][Full Text] [Related]
76. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations. Gund TM; Floyd J; Jung D J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980 [TBL] [Abstract][Full Text] [Related]
77. Studies on the role of the receptor protein motifs possibly involved in electrostatic interactions on the dopamine D1 and D2 receptor oligomerization. Łukasiewicz S; Faron-Górecka A; Dobrucki J; Polit A; Dziedzicka-Wasylewska M FEBS J; 2009 Feb; 276(3):760-75. PubMed ID: 19143836 [TBL] [Abstract][Full Text] [Related]
78. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. Mohr P; Decker M; Enzensperger C; Lehmann J J Med Chem; 2006 Mar; 49(6):2110-6. PubMed ID: 16539400 [TBL] [Abstract][Full Text] [Related]
79. The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Froimowitz M; Cody V Drug Des Discov; 1997 Aug; 15(2):63-81. PubMed ID: 9342550 [TBL] [Abstract][Full Text] [Related]
80. Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R). Stokmaier D; Khorev O; Cutting B; Born R; Ricklin D; Ernst TO; Böni F; Schwingruber K; Gentner M; Wittwer M; Spreafico M; Vedani A; Rabbani S; Schwardt O; Ernst B Bioorg Med Chem; 2009 Oct; 17(20):7254-64. PubMed ID: 19762243 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]